Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration (TGA) regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi’s GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression.
The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. Optimi also noted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies.
For Optimi, which operates a GMP-certified facility in Canada and exports to Australia, these changes could lead to increased demand for its products. The broader eligibility means more psychiatrists and therapy teams can participate, potentially driving higher prescription volumes. The ability to treat patients outside hospital settings also reduces barriers for patients in rural and remote areas, where access to mental health care is often limited.
The TGA’s move signals a growing acceptance of psychedelic-assisted therapies in regulated markets. Australia became the first country to legalize psilocybin and MDMA for psychiatric use in July 2023, and the updated framework aims to refine that system based on real-world data. The absence of serious adverse events since December 2025 is a key safety indicator that could encourage other countries to consider similar programs.
For the broader psychedelic industry, this development offers a template for scaling therapy access while maintaining safety. It also highlights the importance of GMP-compliant manufacturing, as Optimi’s ability to supply consistent, high-quality MDMA and psilocybin positions it to serve this expanding market. Investors and industry observers will likely watch for increased prescription rates and potential reimbursement wins as the framework takes effect.
The full press release detailing the TGA recommendations is available at https://nnw.fm/yYW7j. More information about Optimi Health Corp. can be found on its website at https://www.optimi.net/.
